WCLC 2021 | WCLC 2021 highlights

Jay Lee, MD, UCLA Health, Los Angeles, CA, shares his thoughts on the results of the CodeBreaK 100 trial presented at WCLC 2021, one of the highlights from the meeting. The Phase II study investigated sotorasib, a KRAS G12C inhibitor in advanced or metastatic non-small cell lung cancer (NSCLC). He believes the initial efficacy results of the trial are promising and that targeting this mutation is important as it is common in NSCLC. This interview took place during the IASLC World Conference on Lung Cancer (WCLC) virtual meeting 2021.